ArticleBioanalysis2009
Research Spotlight: New multiparameter bioanalytical technologies for applications in personalized medicine, drug discovery and fundamental biology.
Article in Bioanalysis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic approaches and identification of novel therapeutic targets for alcoholism.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Review
- In silico prediction of a disease-associated STIL mutant and its affect on the recruitment of centromere protein J (CENPJ).FEBS open bio · 2012Article
- Quantitative, label-free detection of five protein biomarkers using multiplexed arrays of silicon photonic microring resonators.Analytical chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The ability to determine expression levels of multiple genetic and/or proteomic signatures simultaneously from the same sample volume is of tremendous importance in a wide range of biomedical applications, including disease diagnostics, drug discovery and fundamental studies of complex biological processes. Unfortunately, many of the tremendously enabling genomic and proteomic technologies available to the academic are not applicable in the clinical setting. Combining traditional chemical and biological insight with cutting-edge concepts from materials science, physics and engineering, our group brings an interdisciplinary approach to developing new tools in order to tackle longstanding refractory problems in the biological sciences - technologies that will enable fundamental biological discovery and, in some applications, expedite the transfer of biomolecular insight to the hands of the physician, where it can directly impact patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.